Oncoinvent ASA
OCIN | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NO0010779341 (+1 more)
- LEI:
- 54930076H5GUZRMSNR39
- Country:
- Norway
- Address:
- Gullhaugveien 7, 0484 Oslo
- Website:
- https://www.oncoinvent.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Oncoinvent ASA is a clinical-stage biotechnology company focused on developing innovative radiopharmaceutical products to improve treatment options for cancer patients. The company's vision is to transform cancer care through direct alpha therapy. Its lead product candidate, Radspherin®, is a novel alpha-emitting therapeutic designed for the localized treatment of cancers within the peritoneal cavity, such as peritoneal metastases. The technology utilizes inorganic microparticles as carriers for alpha-emitters, delivering high-power, short-range radiation directly to tumor sites while aiming to minimize systemic exposure. Oncoinvent is advancing its clinical pipeline, having reported positive data from a Phase 1/2a trial for Radspherin®. The company announced a proposed merger with BerGenBio in 2025.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Oncoinvent ASA.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-27 07:00 |
Earnings Release
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and adv…
|
English | 135.5 KB | |
| 2025-08-27 07:00 |
Investor Presentation
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and adv…
|
English | 1.2 MB | |
| 2025-08-27 07:00 |
Interim Report
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and adv…
|
English | 647.1 KB | |
| 2025-08-27 07:00 |
Earnings Release
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and adv…
|
English | 4.5 KB | |
| 2025-08-22 12:22 |
Report Publication Announcement
Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 Aug…
|
English | 4.2 KB | |
| 2025-08-04 13:53 |
Post-Annual General Meeting Information
Oncoinvent shareholders approve the merger plan with BerGenBio - Attachment: On…
|
Norwegian | 111.8 KB | |
| 2025-08-04 13:53 |
Post-Annual General Meeting Information
Oncoinvent shareholders approve the merger plan with BerGenBio
|
English | 4.4 KB | |
| 2025-07-03 15:45 |
Pre-Annual General Meeting Information
Oncoinvent ASA: Notice of Extraordinary General Meeting - Attachment: Oncoinven…
|
Norwegian | 190.2 KB | |
| 2025-07-03 15:45 |
Pre-Annual General Meeting Information
Oncoinvent ASA: Notice of Extraordinary General Meeting
|
English | 3.6 KB | |
| 2025-06-30 22:11 |
Share Issue/Capital Change
Announcement of fully underwritten rights issue - Attachment: Attachment_overvi…
|
English | 101.2 KB | |
| 2025-06-30 22:11 |
Share Issue/Capital Change
Announcement of fully underwritten rights issue - Attachment: Joint_Press_Relea…
|
English | 143.1 KB | |
| 2025-06-30 22:11 |
Share Issue/Capital Change
Announcement of fully underwritten rights issue
|
English | 20.6 KB | |
| 2025-06-30 22:01 |
M&A Activity
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer ther…
|
English | 136.0 KB | |
| 2025-06-30 22:01 |
M&A Activity
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer ther…
|
English | 19.0 KB | |
| 2025-06-18 08:01 |
Legal Proceedings Report
Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phas…
|
English | 134.6 KB |
Automate Your Workflow. Get a real-time feed of all Oncoinvent ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Oncoinvent ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
